-+ 0.00%
-+ 0.00%
-+ 0.00%
FDA Grants Orphan Drug Designation To Novartis’ Rapcabtagene Autoleucel For Treatment Of Idiopathic Inflammatory Myopathies
Share
Listen to the news

http://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1147426

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending